Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method

23 Aug 2020

Abstract excerpt

The SARS-CoV-2 outbreak caused an unprecedented global public health threat, having a high transmission rate with currently no drugs or vaccines approved. An alternative powerful additional approach to counteract COVID-19 is in silico drug repurposing. The SARS-CoV-2 main protease is essential for viral replication and an attractive drug target. In this study, we used the virtual screening protocol with both...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to SARS-CoV-2 and COVID-19 Research
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32842509
DOI: 10.3390/molecules25173830

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico MethodPMID 32842509Read ↗

Identification of SARS‐CoV‐2 Papain‐like Protease (PLpro) Inhibitors Using Combined Computational Approach**Semantic proximity Read ↗

A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19Semantic proximity Read ↗

Identification of novel transmembrane Protease Serine Type 2 drug candidates for COVID-19 using computational studiesSemantic proximity Read ↗

An Integrative in Silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main ProteaseSemantic proximity Read ↗

Identification of promising high-affinity inhibitors of SARS-CoV-2 main protease from African Natural Products Databases by Virtual ScreeningSemantic proximity Read ↗

In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease InhibitorsSemantic proximity Read ↗

Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV‑2 Main ProteaseSemantic proximity Read ↗

Pharmacophore Analyses of SARS-CoV-2 Active Main Protease Inhibitors Using Pharmacophore Query and Docking StudySemantic proximity Read ↗

Repurposing FDA-approved drugs against the “main protease” pivotal enzyme in COVID-19 virus using computer-aided drug design techniquesSemantic proximity Read ↗

Old Arsenal to Combat New Enemy: Repurposing of Commercially Available FDA Approved Drugs Against Main Protease of SARS-CoV2.Semantic proximity Read ↗

Discovering potent inhibitors against the Mpro of the SARS-CoV-2. A Medicinal Chemistry approach.Semantic proximity Read ↗

Drug Repurposing Against SARS-CoV-2 Using E-Pharmacophore Based Virtual Screening and Molecular Docking with Main Protease as the TargetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.